drugset / Trial / NCT00196963

Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

NCT00196963

Phase 2 Completed 125 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the MenACWY conjugate vaccine when given to healthy subjects aged 15-19 years. The selection of the best formulation will be based on data obtained up to one month after the vaccine dose.

Timeline

Start
2005-03
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MenACWY conjugate vaccine Vaccine
Subject Mencevax™ ACWY Vaccine